Skip to main content

Month: June 2025

TransUnion Announces Earnings Release Date for Second Quarter 2025 Results

CHICAGO, June 27, 2025 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) will publish its financial results for the second quarter ended June 30, 2025, in a press release to be issued at approximately 6:00 a.m. Central Time (CT) on Thursday, July 24, 2025. The company will hold a conference call on the same day at 8:30 a.m. (CT) to discuss its financial results. The press release and a live webcast of the earnings conference call will be available on the TransUnion Investor Relations website at http://www.transunion.com/tru. About TransUnion (NYSE: TRU) TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of...

Continue reading

Kaldvík AS: Annual general meeting held

Frøya, 27 June 2025: The annual general meeting of Kaldvík AS was held today on 27 June 2025 at 12:00 hours (CEST) with approximately 61.24% of all shares entitled to vote present either in person or by proxy. A copy of the minutes is attached to this announcement. All resolutions were approved in accordance with the proposal from the board of directors. For further information, please contact:Roy-Tore Rikardsen, CEO: +354 791 0006 (mobile)Robert Robertsson, CFO: +354 843 0086 (mobile) This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentKaldvik AS AGM minutes 27 June 2025

Continue reading

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series by HonorHealth Research Instituteon June 27, 2025 in Scottsdale, Arizona MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, multi-specific T-cell engagers against solid tumors, particularly for pancreatic cancer, using its novel proprietary...

Continue reading

Arbitral Tribunal acting under ICC Rules of Arbitration issues final award in an arbitration between Agfa-Gevaert and the insolvency receiver of AgfaPhoto GmbH

                                        June 27, 2025 – 1.45 PM CETRegulated information – Contains inside information Arbitral Tribunal acting under ICC Rules of Arbitration issues final award in an arbitration between Agfa-Gevaert and the insolvency receiver of AgfaPhoto GmbH Mortsel, Belgium – June 27, 2025 – 1.45 PM CET An Arbitral Tribunal acting under the International Chamber of Commerce (ICC) Rules of Arbitration has rendered a final award in the last arbitration proceeding with a possible material impact between Agfa-Gevaert and the insolvency receiver of AgfaPhoto GmbH. The Arbitral Tribunal dismissed all claims asserted by the insolvency receiver of AgfaPhoto GmbH relating to an alleged undercapitalization of AgfaPhoto GmbH in connection with Agfa-Gevaert’s carve-out and contribution of its entire consumer imaging business...

Continue reading

Digital Asset Technologies Appoints Marcus Ingram as Chief Executive Officer and Director

VANCOUVER, BC, June 27, 2025 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: EATBF) (FSE: 988) (“DATT” or the “Company”), a technology focused investment issuer, is pleased to announce that Marcus Ingram, the current CEO of its wholly owned portfolio company, LiquidLink, has been appointed as the new CEO and Director of DATT. Mr. Ingram will also continue in his role as CEO of LiquidLink while taking on executive leadership across DATT’s broader portfolio and strategy. This appointment follows the resignation of Young Bann as CEO and Director of DATT. The Company would like to express its sincere gratitude to Mr. Bann for his dedicated service and contributions in leading the Company through its formative period. Mr. Bann will continue as an Advisor to the Company to ensure a smooth transition. Mr. Ingram...

Continue reading

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into a definitive merger agreement (“the Merger Agreement”), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock (“Turnstone common stock”) plus one non-transferable contingent value right (“CVR”). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the Merger Agreement and related transactions.   TermsPursuant and subject to the...

Continue reading

Bunker Hill Announces Election to Issue Shares in Satisfaction of Interest Payment Obligations

KELLOGG, Idaho and VANCOUVER, British Columbia, June 27, 2025 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSXV:BNKR | OTCQB:BHLL) announces that it has elected to issue an aggregate of 15,378,473 shares of common stock of the Company (the “Interest Shares”) in full satisfaction of the interest payable as of June 30, 2025 under certain debt instruments (collectively, the “Interest Payments”), including (i) an aggregate of 1,291,667 Interest Shares to certain holders of 5.0% Series 1 secured convertible debentures (the “Series 1 Debentures”) for the aggregate interest of US$103,333.33 owing thereunder, (ii) an aggregate of 4,260,417 Interest Shares to certain holders of 5.0% Series 2 secured convertible debentures (the “Series 2 Debentures”) for the aggregate interest of US$340,833.33 owing thereunder,...

Continue reading

FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS 

WEST PALM BEACH, FLORIDA, June 27, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has designated a new series of its preferred stock (Series E Cumulative Redeemable Secured Preferred Stock e (the “Series E Preferred Stock”)) and filed the series’ certificate of designation with the Secretary of State of Delaware. The newly designated series of preferred stock includes: (i) a stated value of $25.00 per share, (ii) a 2.5% per annum cash dividend paid semi-annually, (iii) a 5.0% per annum common stock dividend paid semi-annually, and (iv) a security interest in the stock of the Company’s recently formed acquisition vehicle, FOXO Acquisition Corporation. Seamus Lagan, CEO of FOXO stated, “We are excited about taking a critical step as FOXO continues to pursue its...

Continue reading

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan— —With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from prior 2027 net cash guidance)— RESEARCH TRIANGLE PARK, N.C., June 27, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has entered into a definitive agreement to sell its European ORLADEYO® (berotralstat) business to Neopharmed Gentili for up to $264 million. BioCryst plans to use the proceeds from the transaction...

Continue reading

Sale of Custody Business in Hsbc Germany

Press Release 27 June 2025 SALE OF CUSTODY BUSINESS IN HSBC GERMANY HSBC Continental Europe has reached an agreement to sell its custody business in Germany to BNP Paribas S.A, Niederlassung Deutschland (‘BNP Paribas’) (the ‘Potential Transaction’), reinforcing its focus on being the leading corporate and institutional bank in Germany and Europe for international clients. This decision forms part of the simplification strategy of HSBC announced in October 2024. HSBC is focused on increasing its leadership and market share in the areas where it has a clear competitive advantage, and where it has the greatest opportunity to grow and support its clients. This includes connecting European clients to opportunities across HSBC’s international network. For Securities Services, this means focusing on HSBC’s market-leading franchise in Asia and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.